

---

Pharmaceutical and Food Safety Bureau,  
Ministry of Health, Labour and Welfare



Translated by Office of Safety I,  
Pharmaceuticals and Medical Devices Agency



---

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

---

## *Safety Information*

---

PFSB/SD Notification No. 0614-1

June 14, 2013

To: The chairman of the committee on safety of medicines, the Federation of  
Pharmaceutical Manufacturers' Associations of JAPAN

From: Director of Safety Division,  
Pharmaceutical and Food Safety Bureau,  
Ministry of Health, Labour and Welfare

Revision of the Precautions section of the package inserts of  
Recombinant Adsorbed Bivalent Human Papillomavirus-like Particle  
Vaccine (derived from Trichoplusia ni cells) and  
Recombinant Adsorbed Quadrivalent Human Papillomavirus Virus-Like  
Particle Vaccine (Yeast Origin)

Based on gathering, analyzing and reviewing information on the quality, safety and efficacy of recombinant adsorbed bivalent human papillomavirus-like particle vaccine (derived from *Trichoplusia ni* cells) and recombinant adsorbed quadrivalent human papillomavirus virus-like particle vaccine (Yeast Origin), the Ministry of Health, Labour and Welfare determined that the Precautions section of the package inserts of the vaccines should be revised. Please inform relevant parties of this notification to take necessary actions.

The package inserts of recombinant adsorbed bivalent human papillomavirus-like particle vaccine (derived from *Trichoplusia ni* cells) and recombinant adsorbed quadrivalent human papillomavirus virus-like particle vaccine (Yeast Origin) should be revised as per the attached document. And all necessary steps such as providing the information to healthcare professionals should be taken. In addition to that, a notification of change for “Precautions” in package inserts of these vaccines should be submitted to the Director of Office of Safety II, Pharmaceuticals and Medical Devices Agency within one month from the date on which this notification was given.

Attachment:

631 vaccines

**【Nonproprietary Name】**

- Recombinant Adsorbed Bivalent Human Papillomavirus-like Particle Vaccine (derived from Trichoplusia ni cells)
  
- Recombinant Adsorbed Quadrivalent Human Papillomavirus Virus-Like Particle Vaccine (Yeast Origin)

【The content of the measures】Precautions of the immunizations should be revised. The following statement should be added to the “Important Precautions” sections of the vaccines.

“Although the mechanisms of pathogenesis are unclear, severe pain which is not localized at the injection site (e.g. muscle pain, arthralgia and skin pain, etc.), numbness, weakness, etc., may occur after vaccination and these symptoms may persist for long time. Vaccine recipients and their guardians should be instructed to consult a healthcare provider who can provide appropriate medical care including making neurological and immunological differential diagnosis if any abnormalities are observed after vaccination.”